促紅血球生成素刺激劑市場：現況分析與預測（2023-2030）

Erythropoietin Stimulating Agents Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年01月30日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 158 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

促紅血球生成素興奮劑 (ESA) 是刺激紅血球生成的藥物。它特別用於治療慢性腎臟病和癌症引起的貧血。 ESA 模仿促紅血球生成素的作用，促紅血球生成素是一種在腎臟中產生的激素，可刺激骨髓中紅血球的產生。然而，由於存在血液凝固增加和血壓升高等潛在風險，其使用需要仔細監測。其他幾個因素正在推動促紅血球生成素興奮劑的發展，包括越來越多的慢性腎臟病患者和導致貧血的不健康生活習慣。根據美國國立衛生研究院 2022 年 9 月的一項研究，過度吸菸和飲酒等生活方式選擇與鐵代謝相關，並被視為貧血的危險因子。此外，根據BMC 公共衛生局2023 年7 月的數據，不健康生活方式的盛行率分別為86.4% 的飲食、14.5% 的酒精、6.0% 的菸草、72.2% 的體力活動、42.3% 的螢幕時間和63.9% 的睡眠時間。

由於菸酒被認為是貧血的危險因素，全球盛行率不斷上升，促紅血球生成素興奮劑市場預計將維持約8.6%的穩定成長。根據 2021 年全國藥物使用與健康調查 (NSDUH)，2020 年有 2,950 萬名 12 歲及以上的人患有酒精使用障礙 (AUD)。在預測期內，有幾個因素正在推動市場成長，例如癌症發病率急劇上升、對貧血的認識不斷提高以及醫療保健領域投資的增加。例如，根據切薩皮克腫瘤血液學協會研究的數據，到 2022 年 10 月，超過 62% 的轉移性乳癌患者出現貧血。除此之外，促紅血球生成素刺激劑治療效率的加速導致治療過程更快、準確性更高，這也穩定推動促紅血球生成素刺激劑市場的發展。

依產品類型，市場分為依泊汀阿爾法、依泊汀貝塔、達貝泊汀阿爾法等。在全球促紅血球生成素興奮劑市場中，促紅血球生成素-ALPHA細分市場佔據最大份額。阿爾法依泊汀可增加紅血球生成並提高血液中的含氧量，因此該細分市場佔據了市場主導地位。阿爾法依泊汀是促紅血球生成素的合成製劑，促紅血球生成素是一種刺激紅血球生成的荷爾蒙。它用於治療貧血，特別是腎衰竭患者或接受化療等某些治療的患者。癌症發生率的增加正在推動這一領域的發展。例如，根據世界衛生組織 (WHO) 的數據，2020 年，全球有 230 萬名女性被診斷出罹患乳癌，其中 68.5 萬人死亡。因此，在產品類型中，Epoetin Alfa細分市場在2022年佔據了重要的市場份額。

依適應症，市場分為腫瘤學、血液學、腎臟疾病等。由於腎臟疾病盛行率不斷上升，預計腎臟疾病領域在預測期內將佔據相當大的市場。例如，根據美國國家糖尿病、消化和腎臟疾病研究所的數據，美國有近 808,000 人患有末期腎病 (ESRD)。在因慢性腎臟疾病受損的腎臟中，促紅血球生成素的產生減少，這會影響身體製造紅血球的能力。腎臟疾病會破壞身體調節鐵的能力並導致缺鐵性貧血。研究和開發活動的增加也推動了該領域的發展。因此，在這些適應症中，腎臟疾病類別預計在預測期內表現出較高的複合年增長率。

為了更了解促紅血球生成素興奮劑的市場介紹，將市場分為北美（美國、加拿大等北美地區）、歐洲（德國、英國、法國、西班牙、義大利等歐洲地區）、亞太地區（中國、日本、印度、亞太地區其他地區）和世界其他地區。在目前的 2022 年情境中，由於酒精消費增加導致慢性腎臟損傷，以及開發有效促紅血球生成素興奮劑的研發和投資增加，北美將主導市場。例如，2023年9月，美國H. Lee Moffitt癌症中心和研究所研究了canakinumab聯合darbepoetin alfa對既往促紅血球生成素治療失敗的低風險MDS患者的毒性和毒性（ ESA）。我們已經開始了一項臨床試驗來評估療效。政府機構已啟動貧血意識計劃，為患者提供有效的治療。因此，從地區來看，2022年北美將佔據較大的市場份額。

參與市場的主要公司包括F. Hoffmann-La Roche Ltd.、Pfizer Inc.、Thermo Fisher Scientific Inc.、Amgen Inc.、Biocon、Johnson &Johnson Services, Inc.、Teva Pharmaceutical Industries Ltd.、3SBio Group、CELLTRION INC.、Intas Pharmaceuticals Ltd.、Teva Pharmaceutical Industries Ltd.。

Erythropoietin-stimulating agents (ESAs) are medications that stimulate the production of red blood cells. They're often used to treat anemia, especially in conditions like chronic kidney disease or cancer. ESAs mimic the action of erythropoietin, a hormone produced by the kidneys that stimulates red blood cell production in the bone marrow. However, their usage requires careful monitoring due to potential risks, such as increased blood clotting or higher blood pressure. Several other factors, such as rising cases of chronic kidney disorders and unhealthy lifestyles which lead to anemia are leading drivers of erythropoietin-stimulating agents globally. According to the National Institute of Health's study in September 2022, lifestyle choices such as heavy cigarette smoking and alcohol consumption are found to be correlated with iron metabolism and seen as risk factors for anemia. Also, according to the BMC Public Health, in July 2023, the prevalence of unhealthy lifestyles was 86.4% for diet, 14.5% for alcohol, 6.0% for tobacco, 72.2% for physical activity, 42.3% for screen time, and 63.9% for sleep duration.

The Erythropoietin Stimulating Agents Market is expected to grow at a steady rate of around 8.6% owing to the increased prevalence of alcohol and tobacco globally which are seen as risk factors for anemia. According to the 2021 National Survey on Drug Use and Health (NSDUH), 29.5 million people ages 12 and older had Alcohol Use Disorder (AUD) in the year 2020. Several factors, including a surge in the incidence of cancer, increasing awareness regarding anemia, and increased investments in healthcare departments are driving the growth of the market during the forecast period. For instance, in October 2022, according to Chesapeake Oncology Hematology Associates Research, over 62% of patients with metastatic breast cancer developed anemia. Apart from this, accelerated treatment efficiency with erythropoietin stimulating agents has resulted in faster treatment procedures and better accuracy which is also driving this market of erythropoietin stimulating agents at a steady rate.

Based on product type, the market is segmented into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. The epoetin-alfa segment held the maximum share in the global market of erythropoietin-stimulating agents 2022. This segment dominated the market because it helped increase red blood cell production, improving oxygen levels in the blood. Epoetin alfa is a synthetic form of erythropoietin, a hormone that stimulates the production of red blood cells. It's used to treat anemia, particularly in patients with kidney failure or those undergoing certain treatments like chemotherapy. Growing incidences of cancer are driving this segment. For instance, according to the World Health Organization in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. Thus, amongst product types, the epoetin-alfa segment held a significant market share in 2022.

Based on indication, the market is categorized into oncology, hematology, renal diseases, and others. The renal diseases segment is expected to hold a significant share of the market in the forecast period owing to the rising incidences of kidney disorders. For instance, according to the National Institute of Diabetes and Digestive and Kidney Diseases, nearly 808,000 people in the U.S. are living with end-stage renal disease (ESRD). Damaged kidneys in chronic kidney disease may produce less erythropoietin, impacting the body's ability to create red blood cells. Kidney disease can disrupt the body's ability to regulate iron, leading to iron deficiency anemia. This segment is also propelled by rising research and development activities. Thus, amongst indications, the renal diseases category is expected to witness higher CAGR during the forecast period.

For a better understanding of the market adoption of erythropoietin stimulating agents, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing alcohol consumption leading to chronic kidney disorders, and the rising number of research and investments in developing effective erythropoietin-stimulating agents. For instance, in September 2023, U.S-based H. Lee Moffitt Cancer Center and Research Institute initiated a clinical trial for evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA). Government organizations are initiating anemia awareness programs to provide efficient care to patients. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include F. Hoffmann-La Roche Ltd.; Pfizer Inc.; Thermo Fisher Scientific Inc.; Amgen Inc.; Biocon; Johnson & Johnson Services, Inc.; Teva Pharmaceutical Industries Ltd.; 3SBio Group; CELLTRION INC.; Intas Pharmaceuticals Ltd.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Erythropoietin Stimulating Agents Market
2.2. Research Methodology of the Erythropoietin Stimulating Agents Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE ERYTHROPOIETIN STIMULATING AGENTS MARKET

6 ERYTHROPOIETIN STIMULATING AGENTS MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY PRODUCT TYPE

7.1. Epoetin-alfa
7.2. Epoetin-beta
7.3. Darbepoetin-alfa
7.4. Others

8 MARKET INSIGHTS BY INDICATION

8.1. Oncology
8.2. Haematology
8.3. Renal Diseases
8.4. Others

9 MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World